Tabriz University of Medical Sciences Advanced Pharmaceutical Bulletin 2228-5881 16 2 2026 06 15 Next-Generation Targeted Molecular Therapies in Immune-Mediated Inflammatory Diseases 332 342 10.34172/apb.46844 EN Mostafa Akbarzadeh-Khiavi https://orcid.org/0000-0002-1552-6537 Amir-Hossein Olfati Azam Safary https://orcid.org/0000-0002-8997-2003 Journal Article 10.34172/apb.46844 2025 12 04 2026 03 23 Immune-mediated inflammatory diseases (IMIDs) are chronic disorders characterized by dysregulated immunity and loss of self-tolerance. Although significant progress has been made in the management of IMIDs, challenges such as drug resistance, immunogenicity, and limited accessibility continue to impede clinical outcomes. Achieving sustained remission necessitates a transition toward precision medicine that addresses fundamental disease mechanisms. This study examines recent advances in molecular interventions, including cytokine inhibitors, kinase modulators, and B-cell therapies, and emphasizes how these approaches improve remission rates and reduce relapses. Additionally, emerging platforms such as RNA therapeutics, nanomedicine, and chimeric antigen receptor (CAR) cell therapies are discussed, with a focus on their potential to enhance efficacy and prolong clinical response duration. Integrating these innovations with artificial intelligence to identify therapeutic targets, predict patient responses, and optimize drug development is essential to realizing truly personalized, more successful treatments for IMIDs.